SCHEMBL5169747

SCHEMBL5169747

O=C1SC(c2ccccc2)C(=O)N1Cc1ccco1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.51
MAPK1 P28482 2/20 0.51
ALDH1A1 P00352 13/20 0.48
MEN1 O00255 5/20 0.48
KMT2A Q03164 5/20 0.48
MAPT P10636 4/20 0.48
POLB P06746 3/20 0.48
PKM P14618 2/20 0.48
USP2 O75604 2/20 0.48
SMN1; SMN2 Q16637 4/20 0.46
GAA P10253 2/20 0.45
GLA P06280 1/20 0.45
HSD17B10 Q99714 3/20 0.44
KDM4E B2RXH2 2/20 0.44
HPGD P15428 2/20 0.44
HTT P42858 1/20 0.44
TSHR P16473 2/20 0.43
ALOX15 P16050 2/20 0.43
TRPV6 Q9H1D0 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5167815 0.76 ALDH1A1 (0.43) LMNAALDH1A1MEN1KMT2AMAPT
SCHEMBL11276340 0.72 CA2 (0.38) LMNAMAPK1ALDH1A1MEN1KMT2A
SCHEMBL7252297 0.70 POLB (0.55) MAPK1ALDH1A1MEN1KMT2AMAPT
SCHEMBL17263340 0.68 ALDH1A1 (0.53) LMNAMAPK1ALDH1A1MEN1KMT2A
SCHEMBL480278 0.67 ALDH1A1 (0.73) LMNAMAPK1ALDH1A1MEN1KMT2A
SCHEMBL2795967 0.67 ALDH1A1 (0.54) LMNAMAPK1ALDH1A1MEN1KMT2A
SCHEMBL23009248 0.65 KDM4E (0.63) LMNAMAPK1ALDH1A1MEN1KMT2A
SCHEMBL4760288 0.65 ALDH1A1 (0.53) LMNAALDH1A1MEN1KMT2AMAPT
SCHEMBL11272848 0.65 MTNR1A (0.47) MAPK1ALDH1A1POLBGAAKDM4E
SCHEMBL25429949 0.65 MEN1 (0.37) LMNAMAPK1ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070078175-A1 Administration of novel phenylfurylmethylthiazolidine-2,4-dione and phenylthienylmethylthiazolidine-2,4-dione compounds for stimulating or inducing the growth of keratinous fibers and/or slowing loss thereof L'OREAL (FR) 2007-04-05 US claimed
US-20070077215-A1 Administration of phenylfurymethylthiazolidine-2,4-dione or phenylthienymethylthiazolidine-2,4-dione compounds for promoting and/or inducing and/or stimulating the pigmentation of keratinous substances and/or limiting their depigmentation and/or their whitening L'OREAL (FR) 2007-04-05 US claimed
US-12616681-B2 Compositions and methods for treating renal injury CASE WESTERN RESERVE UNIVERSITY (US) 2026-05-05 US disclosed
EP-3883577-B1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY UNIV CASE WESTERN RESERVE (US) 2026-04-08 EP disclosed
US-20260007642-A1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR PROMOTING NEUROGENESIS AND INHIBITING NERVE CELL DEATH UNIV CASE WESTERN RESERVE (US) 2026-01-08 US disclosed
US-20250325524-A1 COMPOSITIONS AND METHODS FOR TREATING RENAL INJURY UNIV CASE WESTERN RESERVE (US) 2025-10-23 US disclosed
EP-3267995-B1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING FIBROSIS UNIV CASE WESTERN RESERVE (US) 2025-10-08 EP disclosed
US-20250304597-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2025-10-02 US disclosed
US-20250295640-A1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING FIBROSIS CASE WESTERN RESERVE UNIVERSITY 2025-09-25 US disclosed
US-20250243217-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2025-07-31 US disclosed
US-12336982-B2 Compositions and methods of modulating short-chain dehydrogenase activity RODEO THERAPEUTICS CORPORATION (US) 2025-06-24 US disclosed
EP-1774958-A1 Use of phenylfurylmethylthiazolidine-2,4-dione or phenylthienylmethylthiazolidine-2,4-dione compounds for promoting and/or inducing and/or stimulating the pigmentation of keratinous substances and/or limiting their depigmentation and/or their whitening L'Oréal (FR) 2007-04-18 EP disclosed
EP-1774958-A1 Use of phenylfurylmethylthiazolidine-2,4-dione or phenylthienylmethylthiazolidine-2,4-dione compounds for promoting and/or inducing and/or stimulating the pigmentation of keratinous substances and/or limiting their depigmentation and/or their whitening L'Oréal (FR) 2007-04-18 EP disclosed
EP-1775294-A1 Phenyl-furyl-methyl-thiazolidine-2,4-dione or phenyl-thienyl-methyl-thiazolidine-2,4-dione compounds; use for stimulating or inducing keratin fibre growth and/or slowing down their loss; compostions thereof L'Oréal (FR) 2007-04-18 EP disclosed
EP-1775294-A1 Phenyl-furyl-methyl-thiazolidine-2,4-dione or phenyl-thienyl-methyl-thiazolidine-2,4-dione compounds; use for stimulating or inducing keratin fibre growth and/or slowing down their loss; compostions thereof L'Oréal (FR) 2007-04-18 EP disclosed
US-20070078175-A1 Administration of novel phenylfurylmethylthiazolidine-2,4-dione and phenylthienylmethylthiazolidine-2,4-dione compounds for stimulating or inducing the growth of keratinous fibers and/or slowing loss thereof L'OREAL (FR) 2007-04-05 US disclosed
US-20070078175-A1 Administration of novel phenylfurylmethylthiazolidine-2,4-dione and phenylthienylmethylthiazolidine-2,4-dione compounds for stimulating or inducing the growth of keratinous fibers and/or slowing loss thereof L'OREAL (FR) 2007-04-05 US disclosed
US-20070078175-A1 Administration of novel phenylfurylmethylthiazolidine-2,4-dione and phenylthienylmethylthiazolidine-2,4-dione compounds for stimulating or inducing the growth of keratinous fibers and/or slowing loss thereof L'OREAL (FR) 2007-04-05 US disclosed
US-20070077215-A1 Administration of phenylfurymethylthiazolidine-2,4-dione or phenylthienymethylthiazolidine-2,4-dione compounds for promoting and/or inducing and/or stimulating the pigmentation of keratinous substances and/or limiting their depigmentation and/or their whitening L'OREAL (FR) 2007-04-05 US disclosed
US-20070077215-A1 Administration of phenylfurymethylthiazolidine-2,4-dione or phenylthienymethylthiazolidine-2,4-dione compounds for promoting and/or inducing and/or stimulating the pigmentation of keratinous substances and/or limiting their depigmentation and/or their whitening L'OREAL (FR) 2007-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070077215-A1 Administration of phenylfurymethylthiazolidine-2,4-dione or phenylthienymethylthiazolidine-2,4-dione compounds for promoting and/or inducing and/or stimulating the pigmentation of keratinous substances and/or limiting their depigmentation and/or their whitening TYR, KRT18, MITF LMNA 1994/4885MAPK1 91/4885ALDH1A1 64/4885
US-20250304597-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY HPGD, GCDH, HPGDS LMNA 1481/4885MAPK1 3373/4885ALDH1A1 126/4885
US-12336982-B2 Compositions and methods of modulating short-chain dehydrogenase activity HPGD, GCDH, HPGDS LMNA 1481/4885MAPK1 3373/4885ALDH1A1 126/4885
US-12616681-B2 Compositions and methods for treating renal injury PTGIS, PTGS1, PTGS2 LMNA 2413/4885MAPK1 1486/4885ALDH1A1 145/4885
US-20250295640-A1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING FIBROSIS GCDH, HPGD, UGDH LMNA 1656/4885MAPK1 3429/4885ALDH1A1 28/4885
US-20070078175-A1 Administration of novel phenylfurylmethylthiazolidine-2,4-dione and phenylthienylmethylthiazolidine-2,4-dione compounds for stimulating or inducing the growth of keratinous fibers and/or slowing loss thereof KRT18, NGF, FGF1 LMNA 2000/4885MAPK1 41/4885ALDH1A1 2150/4885
US-20260007642-A1 INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR PROMOTING NEUROGENESIS AND INHIBITING NERVE CELL DEATH PTGDR, HPGD, PTGDR2 LMNA 2911/4885MAPK1 731/4885ALDH1A1 110/4885
US-20250243217-A1 COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY HPGD, GCDH, HPGDS LMNA 1481/4885MAPK1 3373/4885ALDH1A1 126/4885
US-20250325524-A1 COMPOSITIONS AND METHODS FOR TREATING RENAL INJURY PTGS1, GLS, PTGS2 LMNA 2612/4885MAPK1 3895/4885ALDH1A1 214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.